In December 2005, Eli Lilly and Enterprise agreed to plead responsible and fork out $36 million in connection with the illegal marketing on the drug.[264] Revenue Associates were being experienced to promote Evista for breast most cancers and cardiovascular disease, to prompt or bait questions b